Cargando…
Progress in mesenchymal stem cell–based therapy for acute liver failure
Acute liver failure is a life-threatening clinical syndrome characterized by rapid development of hepatocellular necrosis leading to high mortality and resource costs. Numerous treatment strategies for acute liver failure simply prevent complications and decelerate disease progression. The only cura...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109312/ https://www.ncbi.nlm.nih.gov/pubmed/30143052 http://dx.doi.org/10.1186/s13287-018-0972-4 |
_version_ | 1783350304689881088 |
---|---|
author | Wang, Yong-Hong Wu, Dong-Bo Chen, Bing Chen, En-Qiang Tang, Hong |
author_facet | Wang, Yong-Hong Wu, Dong-Bo Chen, Bing Chen, En-Qiang Tang, Hong |
author_sort | Wang, Yong-Hong |
collection | PubMed |
description | Acute liver failure is a life-threatening clinical syndrome characterized by rapid development of hepatocellular necrosis leading to high mortality and resource costs. Numerous treatment strategies for acute liver failure simply prevent complications and decelerate disease progression. The only curative treatment for acute liver failure is liver transplantation, but there are many restrictions on the application of liver transplantation. In recent years, a growing number of studies have shown that stem cells can effectively treat acute liver failure. Several types of stem cells have been used to study liver diseases; mesenchymal stem cells are most commonly used because they are easy to obtain and present no ethical problems. The aims of this article are to review the current knowledge regarding therapeutic mechanisms of mesenchymal stem cells in acute liver failure, to discuss recent advancements in preclinical and clinical studies in the treatment of mesenchymal stem cells, and to summarize the methodological improvement of mesenchymal stem cell transplantation in treating liver failure. |
format | Online Article Text |
id | pubmed-6109312 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-61093122018-08-29 Progress in mesenchymal stem cell–based therapy for acute liver failure Wang, Yong-Hong Wu, Dong-Bo Chen, Bing Chen, En-Qiang Tang, Hong Stem Cell Res Ther Review Acute liver failure is a life-threatening clinical syndrome characterized by rapid development of hepatocellular necrosis leading to high mortality and resource costs. Numerous treatment strategies for acute liver failure simply prevent complications and decelerate disease progression. The only curative treatment for acute liver failure is liver transplantation, but there are many restrictions on the application of liver transplantation. In recent years, a growing number of studies have shown that stem cells can effectively treat acute liver failure. Several types of stem cells have been used to study liver diseases; mesenchymal stem cells are most commonly used because they are easy to obtain and present no ethical problems. The aims of this article are to review the current knowledge regarding therapeutic mechanisms of mesenchymal stem cells in acute liver failure, to discuss recent advancements in preclinical and clinical studies in the treatment of mesenchymal stem cells, and to summarize the methodological improvement of mesenchymal stem cell transplantation in treating liver failure. BioMed Central 2018-08-24 /pmc/articles/PMC6109312/ /pubmed/30143052 http://dx.doi.org/10.1186/s13287-018-0972-4 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Wang, Yong-Hong Wu, Dong-Bo Chen, Bing Chen, En-Qiang Tang, Hong Progress in mesenchymal stem cell–based therapy for acute liver failure |
title | Progress in mesenchymal stem cell–based therapy for acute liver failure |
title_full | Progress in mesenchymal stem cell–based therapy for acute liver failure |
title_fullStr | Progress in mesenchymal stem cell–based therapy for acute liver failure |
title_full_unstemmed | Progress in mesenchymal stem cell–based therapy for acute liver failure |
title_short | Progress in mesenchymal stem cell–based therapy for acute liver failure |
title_sort | progress in mesenchymal stem cell–based therapy for acute liver failure |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109312/ https://www.ncbi.nlm.nih.gov/pubmed/30143052 http://dx.doi.org/10.1186/s13287-018-0972-4 |
work_keys_str_mv | AT wangyonghong progressinmesenchymalstemcellbasedtherapyforacuteliverfailure AT wudongbo progressinmesenchymalstemcellbasedtherapyforacuteliverfailure AT chenbing progressinmesenchymalstemcellbasedtherapyforacuteliverfailure AT chenenqiang progressinmesenchymalstemcellbasedtherapyforacuteliverfailure AT tanghong progressinmesenchymalstemcellbasedtherapyforacuteliverfailure |